Alcor Scientific Demonstrates Fully-Automated ESR Analyzers
|
By LabMedica International staff writers Posted on 14 Nov 2023 |

ALCOR Scientific (Smithfield, RI, USA) is demonstrating its innovative diagnostic instrumentation and medical devices for the healthcare industry at MEDICA 2023.
Visitors to the ALCOR booth can take a close look at the iSED ESR Analyzer and the miniiSED ESR Analyzer which provide virtually instantaneous results with a fully automated workflow. ALCOR’s iSED capillary photometry technology is based on syllectometry. Photometric rheology is used to quantify the rouleaux formation, which is the earliest and most critical phase of red blood cell sedimentation. Red blood cells are injected into the iSED analyzers’ flow cell which causes them to disaggregate. The flow cell sensors capture the difference in light transmission over time as the injected red blood cells begin to re-aggregate.
The technical innovation of ALCOR’s ESR analyzers consists of “directly” measuring the aggregation of the red blood cells, whereas the traditional methods “indirectly” measure the aggregation of the red blood cells by recording the length at which the red cells settle in a Westergren tube. Like traditional ESR testing, iSED results are provided in mm/hr. iSED technology is highly correlated to the Westergren method, and test results are available in just 15-20 seconds without the drawbacks and inconvenience of traditional ESR testing.
At MEDICA 2023, ALCOR is also presenting SENTINELplus Enteral Feeding Pump which is an enhanced version of the company’s popular SENTINEL feeding pump. It delivers the same simplicity and reliability as its predecessor in a lighter and smaller package. Its bright LED display allows caregivers to simultaneously and conveniently view the infusion rate and volume delivered from a distance. Additionally, the pump retains the operating history until manually erased, even in the event of power failures or when it is turned off. ALCOR is highlighting its SEDiTROL Quality Controls which are bi-level, human-based, whole-blood external controls used to monitor the performance of the iSED, iSED ELITE, and miniiSED ESR analyzers and testing techniques. SEDiTROL controls are derived from human blood to mimic a patient sample and are processed in the same manner as a patient sample. For efficiency and convenience, the controls are stored at room temperature and can be placed directly into the analyzer.
Related Links:
ALCOR Scientific
Latest Medica 2023 News
- Absology Showcases Latest Advancements in Medical Diagnostics
- Noul Showcases AI-Driven Blood and Cancer Diagnostic Platform
- Oruba Presents State-of-the-Art Self-Operating Uroflowmeters
- Awareness Technology Exhibits Incredibly Flexible ChemWell 2 ELISA and Chemiluminescent Analyzer
- BioVendor Group Demonstrates Unique IVD Platform and Immunoblot Test
- Greiner Bio-One Highlights Magnetic 3D Cell Culture Technology
- Fujirebio Showcases Range of Novel Testing Solutions
- Sentinel Diagnostics Demonstrates New SENTiNAT 200 and STAT-NAT Kits for Infectious Diseases
- DiaSys Showcases High Quality Diagnostic Reagents and System Solutions
- Randox Exhibits Full Range of Molecular Diagnostic Solutions
- Bosch Healthcare Presents Vivalytic Point-of-Care PCR System
- CerTest Presents Innovations Related to VIASURE Products
- Vircell Highlights All-in-One CLIA System and Real Time PCR Kits
- Tianlong Showcases Cutting-Edge Products and Innovative Molecular Diagnostic Solutions
- Getein Biotech Exhibits Advanced POCT Analyzers
- LumiraDx Demonstrates Transformative Tests and Technologies
Channels
Clinical Chemistry
view channel
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read more
Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
Alzheimer’s disease develops slowly, and biological changes can appear in blood many years before symptoms. While plasma assays for phosphorylated tau offer earlier detection, discerning whether these... Read moreMolecular Diagnostics
view channel
New Molecular Test Boosts Accuracy of Bile Duct Cancer Diagnosis
Bile duct strictures can arise from cancer or benign disease, but their location within ducts connecting the liver, gallbladder, and intestines complicates evaluation. Standard biopsy and cytology may... Read moreAdaptive PCR Platform Improves Consistency in Small-Batch NGS Workflows
PCR amplification during next-generation sequencing (NGS) library preparation can introduce variability, often requiring manual quantification and risking over-cycling artifacts. The issue is especially... Read more
First IVDR‑Certified IGH Clonality Assay Supports Diagnosis of B-Cell Malignancies
Accurate identification of clonal immunoglobulin heavy chain (IGH) gene rearrangements is central to evaluating suspected B-cell lymphoproliferative disorders, where a single B-cell clone yields a defining... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
Rapid Urine Test Speeds Antibiotic Selection for UTIs
Urinary tract infections are a common reason for antibiotic prescribing and have led to more than 800,000 hospital admissions across England in the past five years, according to National Health Service data.... Read more
WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
Tuberculosis (TB) remains a leading infectious killer, with more than 3,300 deaths and 29,000 new illnesses every day. Diagnostic delays and dependence on centralized laboratory networks continue to impede... Read morePathology
view channel
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read more
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Lunit and CellCarta Collaborate to Expand AI Pathology in CDx Development
Lunit (Seoul, South Korea), a leading provider of AI for cancer diagnostics and precision oncology, and CellCarta (Montreal, QC, Canada), a global contract research organization (CRO) laboratory serving... Read more









